Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more
Lucid Diagnostics Inc (LUCD) - Total Assets
Latest total assets as of September 2025: $53.20 Million USD
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) holds total assets worth $53.20 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lucid Diagnostics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Lucid Diagnostics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lucid Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lucid Diagnostics Inc's total assets of $53.20 Million consist of 81.9% current assets and 18.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.8% |
| Accounts Receivable | $405.00K | 1.3% |
| Inventory | $341.00K | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $736.00K | 2.4% |
| Goodwill | $735.26 Million | 2393.8% |
Asset Composition Trend (2018–2024)
This chart illustrates how Lucid Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lucid Diagnostics Inc's current assets represent 81.9% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 72.8% of total assets in 2024, down from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2395.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 2393.8% of total assets.
Lucid Diagnostics Inc Competitors by Total Assets
Key competitors of Lucid Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Lucid Diagnostics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lucid Diagnostics Inc generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lucid Diagnostics Inc is currently not profitable relative to its asset base.
Lucid Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.18 | 0.09 |
| Quick Ratio | 1.87 | 1.14 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $23.64 Million | $ 2.58 Million | $ -14.27 Million |
Lucid Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Lucid Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 3.97 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | $30.71 Million |
| Market Capitalization | $121.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lucid Diagnostics Inc's assets at a significant premium ( 3.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Lucid Diagnostics Inc's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lucid Diagnostics Inc (2018–2024)
The table below shows the annual total assets of Lucid Diagnostics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.71 Million | +12.63% |
| 2023-12-31 | $27.27 Million | -16.12% |
| 2022-12-31 | $32.51 Million | -44.90% |
| 2021-12-31 | $59.00 Million | +2587.88% |
| 2020-12-31 | $2.19 Million | +112.30% |
| 2019-12-31 | $1.03 Million | +5708.43% |
| 2018-12-31 | $17.80K | -- |